Cytokinetics Inc (CYTK)

8.90
0.17 1.95
NASDAQ : Health Care
Prev Close 8.73
Open 8.77
Day Low/High 8.75 / 9.00
52 Wk Low/High 5.90 / 13.18
Volume 311.42K
Avg Volume 375.20K
Exchange NASDAQ
Shares Outstanding 39.70M
Market Cap 347.81M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cytokinetics Enters Oversold Territory (CYTK)

Cytokinetics Enters Oversold Territory (CYTK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Will Cytokinetics (CYTK) Stock Be Helped by Cardiovascular Drug Advancement?

Will Cytokinetics (CYTK) Stock Be Helped by Cardiovascular Drug Advancement?

Cytokinetics (CYTK) announced Thursday that its cardiac myosin activator drug has been advanced to phase III clinical development.

Cytokinetics And Amgen To Advance Omecamtiv Mecarbil To Phase 3 Clinical Development

Cytokinetics And Amgen To Advance Omecamtiv Mecarbil To Phase 3 Clinical Development

Company Expects the Initiation of Phase 3 Cardiovascular Outcomes Clinical Trial in Q4 2016

Cytokinetics Completes Enrollment In VITALITY-ALS, Phase 3 Clinical Trial Of Tirasemtiv In Patients With ALS

Cytokinetics Completes Enrollment In VITALITY-ALS, Phase 3 Clinical Trial Of Tirasemtiv In Patients With ALS

Results Expected 2H 2017; Open-Label Extension Trial to Begin in Q4 2016

Cytokinetics (CYTK) Is Strong On High Volume Today

Cytokinetics (CYTK) Is Strong On High Volume Today

Trade-Ideas LLC identified Cytokinetics (CYTK) as a strong on high relative volume candidate

Cytokinetics And Astellas Announce Option Right For Tirasemtiv And Expansion Of Global Collaboration For CK-2127107 In ALS

Cytokinetics And Astellas Announce Option Right For Tirasemtiv And Expansion Of Global Collaboration For CK-2127107 In ALS

Cytokinetics to Receive $65 Million in Upfront Payments and $30 Million in Additional Sponsored R&D; Potential for More than $100 Million in Payments Associated with the Exercise of the Option

Cytokinetics (CYTK) Strong On High Relative Volume Today

Cytokinetics (CYTK) Strong On High Relative Volume Today

Trade-Ideas LLC identified Cytokinetics (CYTK) as a strong on high relative volume candidate

Cytokinetics Announces Start Of Phase 2 Clinical Trial Of CK-2127107 In Patients With Chronic Obstructive Pulmonary Disease

Cytokinetics Announces Start Of Phase 2 Clinical Trial Of CK-2127107 In Patients With Chronic Obstructive Pulmonary Disease

 Trial Designed to Assess Effect of Skeletal Muscle Activation to Increase Physical Function and Exercise Tolerance Under Collaboration with Astellas

Cytokinetics (CYTK) Flagged As Strong On High Volume

Cytokinetics (CYTK) Flagged As Strong On High Volume

Trade-Ideas LLC identified Cytokinetics (CYTK) as a strong on high relative volume candidate

Interesting CYTK Put And Call Options For February 2017

Interesting CYTK Put And Call Options For February 2017

Investors in Cytokinetics Inc saw new options become available this week, for the February 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Cytokinetics To Ring Nasdaq Closing Bell To Launch ALS Awareness Month

Cytokinetics To Ring Nasdaq Closing Bell To Launch ALS Awareness Month

Company Leadership Joins The ALS Association to Raise Awareness, Education and Funding for People With ALS and Their Caregivers

Cytokinetics, Inc. Reports First Quarter 2016 Financial Results

Cytokinetics, Inc. Reports First Quarter 2016 Financial Results

VITALITY-ALS on Track to Complete Patient Enrollment in 1H 2016

Short Interest Drops 10.6% For CYTK

Short Interest Drops 10.6% For CYTK

The most recent short interest data has been released by the NASDAQ for the 03/31/2016 settlement date, which shows a 570,528 share decrease in total short interest for Cytokinetics Inc , to 4,818,256, a decrease of 10.59% since 03/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Commit To Purchase Cytokinetics At $6, Earn 31.8% Annualized Using Options

Commit To Purchase Cytokinetics At $6, Earn 31.8% Annualized Using Options

Investors eyeing a purchase of Cytokinetics Inc shares, but tentative about paying the going market price of $7.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $6 strike, which has a bid at the time of this writing of 70 cents.